Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

Inclusion Criteria

• •Age: 18 to 75 years, Male or Female
• •Histological or cytologically diagnosis of non-small cell lung cancer
• •Recurrent or metastatic after surgical treatment
• •The pathology must be an assessable disease, signal lesion not exceeding 3 cm in diameter (measurable by CT scan or MRI)，number of Lymph node metastasis is less than 5
• •Refractory to standard treatments (e.g., chemotherapy, radiation, etc.)
• •No chemotherapy and radiation therapy to be planned recently
• •Patients must have a Karnofsky performance status greater than or equal to 70%
• •Life expectancy greater than 3 months
• •Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure
• •Agree that progress of the disease must be radiographically measurable by computerized tomography (CT) scanning technique or magnetic resonance imaging (MRI) (per RECIST1.1 criteria)
• •Agrees to participate in long-term follow-up for up to 3 years, if received NK and NKT infusion
• •Laboratory values within the following ranges prior to receiving treatment of study agent: Peripheral blood cells \>3×10\^9 /L; Number of lymphocytes \>1.0×10\^9 /L; Lymphocyte ratio \>18%; INR\<1.5.